戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  enzybiotic cocktail consisting of CHAPK and lysostaphin.
2 determined by ELISA and by neutralization of lysostaphin.
3 not alter the observed therapeutic values of lysostaphin.
4 X-100-induced autolysis and also to lysis by lysostaphin.
5 S. aureus strain for 72 h in the presence of lysostaphin.
6          A single intravitreous injection of lysostaphin (0.1%) sterilized all eyes of immunized and
7 a single intravitreous injection (0.1 mL) of lysostaphin (0.1%).
8  were treated either topically with drops of lysostaphin (0.3%) or with a single intravitreous inject
9  S. aureus can be rescued by the addition of lysostaphin, a bacterial endopeptidase active at neutral
10 coccus simulans bv. staphylolyticus secretes lysostaphin, a bacteriocin that cleaves pentaglycine cro
11             Staphylococcus simulans secretes lysostaphin, a bacteriolytic enzyme that cleaves staphyl
12             Staphylococcus simulans secretes lysostaphin, a bacteriolytic enzyme that specifically bi
13 stitutions enables secretion of Gln(125,232)-lysostaphin, a bioactive variant.
14 surface protein is removed by treatment with lysostaphin, a glycyl-glycine endopeptidase that separat
15                        Structural studies of lysostaphin, a PG lytic enzyme (autolysin), have suggest
16 to cross-bridges and to confer resistance to lysostaphin, a secreted bacteriocin that cleaves the pen
17 gp13 and homologous residues in the LytM and lysostaphin active sites facilitate hydrolysis of the pe
18 ral new therapeutic agents (e.g. daptomycin, lysostaphin and a Staphylococcus aureus vaccine) are in
19 endopeptidases such as Staphylococcus aureus lysostaphin and LytM, and to DD-endopeptidases involved
20  of cell walls by autolytic enzyme extracts, lysostaphin and mutanolysin.
21 ity and the bond cleavage of the bactericide lysostaphin and the S. aureus PG hydrolase LytM.
22                           The sensitivity to lysostaphin and vancomycin were compared for 34 MRSA and
23 thelial defects (ISP546) were susceptible to lysostaphin, and inhibition of lysostaphin when harvesti
24                                         Anti-lysostaphin antibody titers were determined by ELISA and
25 -infected eyes, despite the presence of anti-lysostaphin antibody.
26 netic engineering, transgenic cows secreting lysostaphin at concentrations ranging from 0.9 to 14 mic
27                     SH3b domains from either lysostaphin (bacteriocin) or LysK (phage endolysin) resu
28                                              Lysostaphin bound to the cell wall envelopes of lyrA mut
29               Rabbits were immunized against lysostaphin by subcutaneous, intranasal, or topical rout
30 anchored proteins, but it can be detected in lysostaphin cell wall extracts.
31 glycan-targeting glycylglycine endopeptidase lysostaphin, compared to the wild type.
32 ate of autolysis and increased resistance to lysostaphin degradation and host cell-mediated killing.
33 opeptide 12, its peptide derivative, and its lysostaphin degradation products by high pressure liquid
34 erformance liquid chromatography analysis of lysostaphin digests of peptidoglycan suggest an increase
35                      Thus, the CWT domain of lysostaphin directs the bacteriocin to cross-linked pept
36            We have discovered that the LytM (lysostaphin)-domain containing factors of E. coli (EnvC,
37 estion with the glycyl-glycine endopeptidase lysostaphin followed by the pneumococcal N-acetylmuramyl
38 ity with the N-terminal region of the mature lysostaphin from Staphylococcus simulans and 50% identit
39 sin CHAPK and the staphylococcal bacteriocin lysostaphin have been co-administered in a thermally tri
40 l pattern of beta-sheets are conserved among lysostaphin homologs (such as LytM of Staphylococcus aur
41  as little as 3 micrograms/ml [corrected] of lysostaphin in milk.
42  gene directed the secretion of Gln(125,232)-lysostaphin into milk, exhibit substantial resistance to
43                  However, we show that while lysostaphin is genuinely a glycyl-glycine hydrolase, Lyt
44 terminal cell wall-targeting domain (CWT) of lysostaphin is required for selective binding of this ba
45                                              Lysostaphin is very effective in treating keratitis medi
46                                 The protein, lysostaphin, is a peptidoglycan hydrolase normally produ
47                        ALE-1, a homologue of lysostaphin, is a peptidoglycan hydrolase that specifica
48  of action of PG hydrolases characterised as lysostaphin-like endopeptidases have remained elusive.
49  mapped to envC (yibP), proposed to encode a lysostaphin-like, metallo-endopeptidase that is exported
50                              The addition of lysostaphin, lysozyme or buffer ATL (a tissue lysis buff
51 tudy of S. aureus mutants with resistance to lysostaphin-mediated killing has revealed biosynthetic p
52                                            A lysostaphin molecule lacking the C-terminal targeting si
53 9 or 10 to 15 hours postinfection with 0.28% lysostaphin or 5.0% vancomycin.
54 zed from the peptidoglycan by treatment with lysostaphin or phi11 hydrolase and identified COOH-termi
55 periments were performed to demonstrate that lysostaphin penetrated the cornea to kill bacteria in vi
56 r, but unlike observed earlier both LytM and lysostaphin prefer the D-Ala-Gly cross-linked part of ma
57                   By contrast, lysozyme plus lysostaphin produced sufficient DNA across all 20 specie
58  wall of S.aureus consisted of 92 C-terminal lysostaphin residues.
59 son insertion in SAV2335, herein named lyrA (lysostaphin resistance A), did not cause gross alteratio
60          Other lyr mutants with intermediate lysostaphin resistance carried bursa aurealis insertions
61                                              Lysostaphin resistance of lyrA mutants is attributable t
62 ted protease domain, caused a high degree of lysostaphin resistance, similar to the case for a previo
63  aureus strain Newman transposon mutants for lysostaphin resistance.
64 tein also affects the autolytic activity and lysostaphin sensitivity of the bacteria, suggesting that
65 induction levels and decreased autolysis and lysostaphin sensitivity was found between strains.
66 daSa2 endopeptidase domain by either LysK or lysostaphin SH3b domain differed by no more than a facto
67 normal and immunized rabbits with keratitis, lysostaphin significantly reduced the log CFU to less th
68 to staphylococci, whereas murein monomers or lysostaphin-solubilized cell wall fragments did not.
69 to two surface proteins (138 and 127 kDa) of lysostaphin-solubilized S. aureus.
70 ith early therapy (4 -9 hours postinfection) lysostaphin sterilized all MRSA 301-infected corneas, wh
71 ncentrations were at least 19-fold lower for lysostaphin than for vancomycin.
72 tensively diminished sensitivity to lysis by lysostaphin, the ability to form a biofilm, and a total
73 cts were observed with the administration of lysostaphin to either normal or immunized rabbit eyes.
74 reactions were produced by administration of lysostaphin to immunized rabbits.
75  presents a new selectivity method involving lysostaphin together with a CMOS-compatible impedance se
76 etrated the cornea to kill bacteria in vivo; lysostaphin-treated eyes were found to recover from infe
77 ours postinfection) the residual bacteria in lysostaphin-treated eyes were significantly less numerou
78                                              Lysostaphin treatment of immunized rabbits was effective
79 usceptible to lysostaphin, and inhibition of lysostaphin when harvesting corneas did not alter the ob
80 e M1 muramidase and decreased sensitivity to lysostaphin, which is a reversal of the susceptibility p